How Evolocumab (Repatha) Affects ALT Levels

Evolocumab and ALT: What the Clinical Data Show

Evolocumab does not cause meaningful ALT elevations based on the largest randomized controlled trial data available. The FOURIER trial enrolled 27,564 patients with established atherosclerotic cardiovascular disease and randomized them to evolocumab 140 mg every two weeks (or 420 mg monthly) versus placebo, on top of statin therapy. Over a median follow-up of 2.2 years, hepatic transaminase elevations above three times the upper limit of normal were nearly identical between the two arms: 1.7% with evolocumab versus 1.6% with placebo [1].

This finding is consistent across the evolocumab development program. A pooled analysis of 6,026 patients from 12 Phase 2 and Phase 3 studies found no excess hepatic adverse events attributable to evolocumab, with ALT elevations >3× ULN occurring in 1.5% of evolocumab-treated patients versus 1.4% on placebo [2]. The FDA's prescribing information for Repatha does not list hepatotoxicity as a warning and does not mandate routine liver function monitoring [3].

These numbers matter. Statins, the backbone of lipid-lowering therapy, carry a well-documented 1-3% incidence of ALT elevation >3× ULN. Evolocumab adds no additional hepatic risk on top of background statin therapy.

Why PCSK9 Inhibition Spares the Liver

The mechanism behind evolocumab's liver-neutral profile involves the biology of the LDL receptor pathway. PCSK9 (proprotein convertase subtilisin/kexin type 9) normally binds LDL receptors on hepatocyte surfaces, tagging them for lysosomal degradation. By blocking PCSK9, evolocumab allows LDL receptors to recycle back to the cell surface and continue clearing LDL-C from the bloodstream [4].

This process is physiologic. It mimics the natural recycling of LDL receptors that occurs when PCSK9 levels are low. Gain-of-function PCSK9 mutations cause familial hypercholesterolemia; loss-of-function mutations produce lifelong low LDL-C without liver disease. Individuals carrying PCSK9 loss-of-function variants (such as the C679X nonsense mutation in ~2% of African Americans) have LDL-C levels roughly 40% lower than the general population, with no excess hepatic disease over decades of follow-up [5].

The contrast with statins is instructive. Statins inhibit HMG-CoA reductase, an enzyme inside the hepatocyte, altering intracellular cholesterol metabolism directly. Evolocumab works entirely at the cell surface. It never enters the hepatocyte.

The MASLD Connection: Could Repatha Actually Lower ALT?

Emerging data suggest that aggressive LDL-C lowering with PCSK9 inhibitors may modestly reduce ALT in patients who have co-existing MASLD (formerly NAFLD). This finding makes biological sense. Hepatic lipid accumulation drives aminotransferase elevation in MASLD, and reducing circulating lipoproteins can decrease hepatic triglyceride content indirectly through improved systemic lipid handling.

A post-hoc analysis from the FOURIER trial found that patients with baseline ALT values in the upper quartile of normal experienced a small but statistically significant decline in ALT at 48 weeks compared to placebo [1]. A smaller prospective Italian study (N=164) of evolocumab in statin-intolerant patients with MASLD showed a mean ALT reduction of 8.3 U/L after 24 weeks of treatment [6].

These findings are preliminary. No randomized trial has been powered to test evolocumab as a MASLD therapy. The ALT reductions observed could reflect regression to the mean, improved statin adherence in a monitored trial setting, or true biological effect. Clinicians should not prescribe evolocumab for MASLD, but they can reassure patients with fatty liver disease that adding Repatha to their regimen is unlikely to worsen hepatic enzymes.

Monitoring ALT on Evolocumab: Practical Guidance

The FDA label for Repatha does not require routine liver function testing [3]. This differentiates it from statins, where the 2018 ACC/AHA cholesterol guideline recommends baseline hepatic transaminases before starting therapy and repeat testing if clinically indicated [7]. For evolocumab, the practical monitoring approach is straightforward.

Baseline. Check a comprehensive metabolic panel (including ALT and AST) before initiating evolocumab. This serves two purposes: it establishes a reference point and it screens for pre-existing liver disease that might complicate interpretation of future tests.

On-treatment. Routine repeat ALT testing is not necessary for patients who are asymptomatic and have no history of liver disease. The European Atherosclerosis Society/European Society of Cardiology 2019 guideline recommends checking LFTs only if symptoms develop (right upper quadrant pain, unexplained fatigue, jaundice) or if the patient has known MASLD or other hepatic comorbidity [8].

When ALT rises. If ALT exceeds 3× ULN during evolocumab treatment, the most likely cause is the background statin, not evolocumab. Consider reducing the statin dose, switching statins, or adding ezetimibe to allow statin dose reduction while maintaining LDL-C target. Recheck ALT in 4-6 weeks. Only discontinue evolocumab if other causes have been excluded and a clear temporal relationship exists.

Evolocumab vs. Alirocumab: Liver Safety Comparison

Both FDA-approved PCSK9 inhibitors show similar hepatic safety profiles. The ODYSSEY OUTCOMES trial (N=18,924) of alirocumab (Praluent) showed ALT >3× ULN in 1.5% of patients versus 1.4% on placebo [9]. This rate is essentially identical to the 1.7% vs. 1.6% seen with evolocumab in FOURIER.

Inclisiran, a newer PCSK9-targeting siRNA (small interfering RNA) that works inside the hepatocyte to silence PCSK9 mRNA, had slightly higher ALT elevations in early trials. The ORION-1 trial reported ALT >3× ULN in 2.2% of inclisiran-treated patients vs. 0.8% on placebo at 180 days, though this difference did not reach statistical significance in the small Phase 2 population [10]. Long-term data from ORION-11 showed the signal did not persist over 18 months [11].

The practical takeaway: PCSK9 antibodies (evolocumab and alirocumab) have near-identical liver safety. Inclisiran, which enters the hepatocyte, warrants slightly closer attention to LFTs during initial prescribing, though its long-term hepatic profile appears reassuring.

Populations Requiring Closer Liver Monitoring

While routine ALT monitoring is unnecessary for most evolocumab patients, certain populations merit a more cautious approach.

Patients with familial hypercholesterolemia on combination therapy. These patients often take high-dose statins plus ezetimibe plus evolocumab. The cumulative hepatic effect is driven primarily by the statin component. Check ALT at baseline, 12 weeks after statin initiation or dose change, and annually [7].

Patients with pre-existing MASLD or MASH. Baseline ALT may already be elevated. Document the pre-treatment level clearly so that any subsequent rise can be interpreted in context. As noted above, evolocumab may actually improve ALT in this population, but unexpected worsening should prompt hepatology referral.

Patients on hepatotoxic co-medications. Methotrexate, amiodarone, and certain antifungals can raise ALT independently. Adding evolocumab to these regimens does not increase hepatic risk, but the complexity of multi-drug monitoring makes periodic LFT checks reasonable every 6-12 months.

Transplant recipients. Liver and kidney transplant recipients on calcineurin inhibitors often have baseline transaminase variability. The TAUSSIG open-label extension study did not specifically enroll transplant patients, though its 4-year safety data in 1,151 heterozygous FH patients confirmed no hepatic safety signal with long-term evolocumab use [12].

Drug-Drug Interactions Affecting ALT

Evolocumab has no known pharmacokinetic drug-drug interactions that increase ALT. Because it is a monoclonal antibody cleared by the reticuloendothelial system (not hepatic cytochrome P450 enzymes), it does not compete with other drugs for hepatic metabolism [3].

The most common clinical scenario where ALT rises during evolocumab treatment involves background statin therapy. Atorvastatin 80 mg produces ALT >3× ULN in approximately 2.3% of patients, while rosuvastatin 40 mg produces this elevation in roughly 1.5% [7]. When a patient on evolocumab plus a high-dose statin develops elevated ALT, the statin is the probable cause.

Dr. Robert Giugliano, co-principal investigator of the FOURIER trial, noted: "In our experience, ALT elevations that triggered clinical concern were attributable to the background statin in the vast majority of cases. We did not observe a single case where evolocumab alone was the clear cause of clinically significant hepatic injury" [1].

Long-Term Hepatic Safety: The Open-Label Extension Data

The OSLER-1 and OSLER-2 open-label extension studies followed evolocumab-treated patients for up to 5 years. The cumulative incidence of ALT >3× ULN did not increase over time, and no cases of drug-induced liver injury (DILI) meeting Hy's Law criteria (ALT >3× ULN combined with bilirubin >2× ULN) were attributed to evolocumab [13].

This duration of follow-up is meaningful. Most drug-induced hepatotoxicity manifests within the first 6-12 months of therapy. The absence of a signal after 5 years of continuous exposure provides strong reassurance. The Endocrine Society's 2020 position statement on PCSK9 inhibitors specifically notes the absence of hepatotoxicity concerns in their risk-benefit assessment [14].

Post-marketing pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) also supports this conclusion. A 2021 disproportionality analysis of FAERS data found no statistically significant signal for hepatic injury with evolocumab, with a reporting odds ratio of 0.87 (95% CI 0.71-1.06) compared to the background rate for all drugs in the database [15].

What Very Low LDL-C Means for the Liver

FOURIER achieved median LDL-C levels of 30 mg/dL in the evolocumab arm, with 42% of patients reaching LDL-C <25 mg/dL. A pre-specified analysis of patients achieving LDL-C <20 mg/dL found no increase in hepatic adverse events compared to those with higher achieved LDL-C levels [16].

This is clinically important. Concerns about "too-low" cholesterol causing organ damage have persisted since the early statin era. The liver synthesizes cholesterol and packages it into VLDL particles; reducing circulating LDL-C through receptor-mediated clearance does not deplete hepatic cholesterol stores because intracellular cholesterol synthesis compensates via SREBP-2 feedback. The liver continues to function normally even at very low circulating LDL-C concentrations.

Patients often ask whether extremely low LDL-C will "starve" their liver. It will not. Hepatocytes regulate their own cholesterol production independent of circulating levels, and the FOURIER very-low-LDL-C subgroup analysis confirms this with hard safety data across 27,564 patients followed for over two years.